SUMMARY Thirty five individual macro EMG motor unit potentials in 13 patients with motor neuron disease were recorded every 15 minutes during a 2 hour period. No significant change in amplitude or area was seen in 15 control units in nine patients or in 20 units in 11 patients receiving RX77368 0-2-0-3 mg/kg. The findings provide no evidence for an action of this long acting TRH analogue on the peripheral territory of motor units in motor neuron disease.
There is evidence that high dose thyrotropin releasing hormone (TRH) and an analogue with a dimethyl substitution in the prolineamide end of the molecule (RX77368) can produce temporary change in muscle force, increase in fasciculations, decrease in spasticity and improvement in certain parameters of bulbar function in patients with motor neuron disease.1 2 The mechanisms mediating such pharmacological actions are unknown. TRH and analogues have an excitatory action on anterior horn cells in the frog,34 toad,5 rat6-9 and cat.10 F and H wave studies in man suggest an action of native TRH in spinal interneurons. '1 12 In previous studies"3 in motor neuron disease, RX77368 produced an acute 25-30% increase in mean corrected fibre density (FD-1) and in mean Macro EMG (MAC) median amplitude and area in brachial biceps muscle. The drug produced no significant change in the mean percentage of individual MAC potentials with amplitude or area above the upper limit of normal.'3 There was no change in the mean amplitude of the compound muscle action potential (MAP) of biceps obtained by stimulation at Erbs point. Repetitive stimulation showed no significant decrement in the MAP response of abductor digiti minimi. The findings were interpreted as consistent with a "central", direct or indirect, action of RX77368 on anterior horn cells. They suggested a change in recruitment order and/or in activa-tion threshold of pathological motor units.
If the observed changes in MAC and FD with RX77368 are not accounted for by a change in the functional peripheral territory of individual motor units it would be expected that no significant change in MAC amplitude and area would occur in such single motor units followed during the period of drug infusion.
We report the results obtained in 35 single motor units followed with the MAC technique for 2 hours during or without infusion of RX77368.
Material and methods
Thirteen patients with motor neuron disease participated. Eleven received L-pyroglutamyl L hystidyl L-3,3 dimethylprolineamide (RX77368) over 2 hours. Seven of them also had control recordings at least 7 days after or before drug infusion. Two 4) .
An analysis of variance was used for statistical comparisons or control and drug units at each temporal sampling point.
All patients gave written informed consent. The study was approved by the local Ethical Committee. The baseline mean values for MAC amplitude and area for control motor units and for those followed during drug infusion were very close. The number of baseline MAC motor units with amplitude above the normal limit and the number of patients in whom they were recorded were both also similar in the control and drug groups (table 2) . The mean percentage standard error of the baselines for all motor units was 2 15% (n = 35; min 0-58, max 7 84) for MAC amplitude and 2-48% (n = 29; min 0-25, max 5 95) for MAC area (fig 4) .
The amplitude of all MAC potentials during 2 hour recordings fell within 99% confidence limits of mean baseline values, both for control motor units (96 potentials) and drug motor units (133 potentials). The same was true for area of all control MAC potentials (n = 84). Only one of 102 areas of MAC potentials during drug infusion fell outside this limit but was inside 95% confidence limits of mean baseline. The dose given was smaller (0-2 mg/kg) than in the previous study (0-3 mg/kg)'3 in 10 of the patients because of the need to reduce side effects. The clinical effects, however, including increase in fasciculations, change in muscle force and shivering were comparable with 0-2 and 0-3 mg/kg.2 17
The findings of this study support the previous hypothesis that the acute action of RX77368 on MAC and FD parameters is the result of a direct or indirect "central" effect of this analogue on motor neurons. 13 We are grateful to the following physicians for referring patients: C Evans, C Hawkes, J Jestico, R McKeran, A Turner, S Wilson. The pathological anatomy was based on three specimens. They concluded "when the lesion occupies the external nucleus (external and posterior part) extending through the internal and median nuclei of the thalamus, involving only a part of the fibres of the posterior limb of the internal capsule, the clinical picture of the thalamic syndrome results."
It was in 1923 that Foix and Masson showed the most common cause was "Le syndrome de l'artere cerebrale posterieure".3 JMS PEARCE
